Nine years without a new FDA-approved therapy for MDS: How can we break through the impasse?

Research output: Contribution to journalArticle

Abstract

The myelodysplastic syndromes (MDSs) are a heterogeneous collection of clonal hematopoietic malignancies that compromise a large subgroup of the myeloid neoplasms and collectively are the most common acquired adult bone marrow failure syndromes. Currently, only 3 agents are approved for the treatment of MDS by the US Food and Drug Administration (FDA): azacitidine, decitabine, and lenalidomide. The latter drug, approved in 2006, is the most recent agent approved by the FDA for MDS and there has been mediocre success with novel agents for the past 9 years. The heterogeneity of MDS as a disease group is likely to be a strong contributor to this slow progress but recent developments in molecular characterization of MDS are improving diagnostic accuracy, providing insights into pathogenesis and refining our prognostic ability in the field. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

Original languageEnglish (US)
Pages (from-to)308-316
Number of pages9
JournalHematology
Volume2015
Issue number1
StatePublished - Dec 5 2015

Fingerprint

Myelodysplastic Syndromes
United States Food and Drug Administration
decitabine
Therapeutics
Azacitidine
Hematologic Neoplasms
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology

Cite this

Nine years without a new FDA-approved therapy for MDS : How can we break through the impasse? / Dezern, Amy.

In: Hematology, Vol. 2015, No. 1, 05.12.2015, p. 308-316.

Research output: Contribution to journalArticle

@article{8ce814cfef564604afe6670336f90ee9,
title = "Nine years without a new FDA-approved therapy for MDS: How can we break through the impasse?",
abstract = "The myelodysplastic syndromes (MDSs) are a heterogeneous collection of clonal hematopoietic malignancies that compromise a large subgroup of the myeloid neoplasms and collectively are the most common acquired adult bone marrow failure syndromes. Currently, only 3 agents are approved for the treatment of MDS by the US Food and Drug Administration (FDA): azacitidine, decitabine, and lenalidomide. The latter drug, approved in 2006, is the most recent agent approved by the FDA for MDS and there has been mediocre success with novel agents for the past 9 years. The heterogeneity of MDS as a disease group is likely to be a strong contributor to this slow progress but recent developments in molecular characterization of MDS are improving diagnostic accuracy, providing insights into pathogenesis and refining our prognostic ability in the field. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.",
author = "Amy Dezern",
year = "2015",
month = "12",
day = "5",
language = "English (US)",
volume = "2015",
pages = "308--316",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Nine years without a new FDA-approved therapy for MDS

T2 - How can we break through the impasse?

AU - Dezern, Amy

PY - 2015/12/5

Y1 - 2015/12/5

N2 - The myelodysplastic syndromes (MDSs) are a heterogeneous collection of clonal hematopoietic malignancies that compromise a large subgroup of the myeloid neoplasms and collectively are the most common acquired adult bone marrow failure syndromes. Currently, only 3 agents are approved for the treatment of MDS by the US Food and Drug Administration (FDA): azacitidine, decitabine, and lenalidomide. The latter drug, approved in 2006, is the most recent agent approved by the FDA for MDS and there has been mediocre success with novel agents for the past 9 years. The heterogeneity of MDS as a disease group is likely to be a strong contributor to this slow progress but recent developments in molecular characterization of MDS are improving diagnostic accuracy, providing insights into pathogenesis and refining our prognostic ability in the field. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

AB - The myelodysplastic syndromes (MDSs) are a heterogeneous collection of clonal hematopoietic malignancies that compromise a large subgroup of the myeloid neoplasms and collectively are the most common acquired adult bone marrow failure syndromes. Currently, only 3 agents are approved for the treatment of MDS by the US Food and Drug Administration (FDA): azacitidine, decitabine, and lenalidomide. The latter drug, approved in 2006, is the most recent agent approved by the FDA for MDS and there has been mediocre success with novel agents for the past 9 years. The heterogeneity of MDS as a disease group is likely to be a strong contributor to this slow progress but recent developments in molecular characterization of MDS are improving diagnostic accuracy, providing insights into pathogenesis and refining our prognostic ability in the field. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

UR - http://www.scopus.com/inward/record.url?scp=85010943886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010943886&partnerID=8YFLogxK

M3 - Article

C2 - 26637738

AN - SCOPUS:85010943886

VL - 2015

SP - 308

EP - 316

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

IS - 1

ER -